Introduction
Since the elucidation of the chemistry and endocrinology of the luteinizing hormone-releasing hormone (LHRH), [1, 2] , < Glu-His-Trp-SerTvr-Gly-Leu-Arg-Pro-Gly-NHo, several research groups sought to achieve an extraordinarily effective antagonist of this hormone which might function as a contraceptive for humans. Since 1973, these research groups have made stepwise progress in the design and synthesis of antagonists, and it was found that exemplary antagonists do show antiovulatory activity in a primate [3] , as well as in the rat models.
Present objectives of these research groups are the design of antagonists which are more potent, have prolonged action, and oral activity.
We have studied an approach, by increasing the number of D-amino acids in an analog, not only toward increased potency, but toward a peptide of greater stability to proteolytic enzymes. 0340-5087/82/0700-904/S 01.00/0 Previously, our studies [4] and those of others had emphasized position 1. and it had been learned that reasonably potent antagonists may have either the L-or the D-configuration in position 1 as well as more than one amino acid moiety [5. 6] i.e., undecapeptides, etc.
Many investigators found that single substitutions can be detrimental in one analog, but beneficial in an analog having a different sequence. For example, replacing D-Phe by D-pClPhe in [D-Phe 2 , D-Ala 6 ]-LHRH decreased antiovulatory activity [7] , but the same change in the sequence [N-Ac-Thr 1 . D-Phe 2 .D-Trp 3 > 6 ]-LHRH increased inhibitory activity in vitro as well as antiovulatory activity [6, 8] . An example of detrimental and beneficial effects on activity by an exchange of configuration in position 1 are the two peptides, [D-Phe 2 , D-Trp 3 , D-Phe 6 ]-LHRH, [9] , and [D-Phe 2 ,Pro 3 . D-Phe 6 ]-LHRH. [10] , which differ by D-Trp 3 and Pro 3 , respectively. When < Glu was changed to D-< Glu in position 1 for the first of these two analogs, the antiovulatory potency was increased but when < Glu in position 1 of the second of these two analogs was changed to D-< Glu, the antiovulatory activity decreased [11] .
[N-Ac-Thr 1 , D-Phe 2 , D-Trp 3 -6 ]-LHRH has a well-tested antiovulatory activity [8] . For this antagonist, as a model analog, we now report the effects on antiovulatory activity of introducing one. 
Experimental Section
Amino acid derivatives were purchased from Peninsula Laboratories (San Carlos, CA). The aamino functions were protected by the BOC-group. except for Arg which had the AOC-group. Sidechain functions were protected by Z-for Ser and Thr, Tos-for Arg, and o-Br-Z for Tyr. Benzylhydrylamine (BHA) resin hydrochloride was obtained from Beckman Bioproducts (Palo Alto, CA). Dicyclohexylcarbodiimide and triethvlamine were distilled prior to use. All other chemicals were reagent grade.
Synthesis
The peptides were synthesized by the solid-phase method using a Beckman Model 990 peptide synthesizer. The attachment of the first amino acid was achieved by using the double-coupling procedure.
The coupling program during the peptide chain elongation involved the following successive operations (mix-time): 1, CH2C12 (2 x, 2 min); 2, 50% TFA in CH2CI2, w/v (1 X, 2 min); 3, 50% TFA in CH2CI2, w/v (1 x. 30 min); 4. CH2C12 (3x, 2 min); 5. 2-propanol (2 x. 2 min); 6. CH2C12 (4x, 2 min); 7. 10% NEt3 in CH2C12 v/v (2x, 2 min); 8, 10% NEt3 in CH2CI2 v/v (1 x, 10 min); 9. CH2C12 (4 x, 2 min); 10, amino acid derivative in CH2CI2 (threefold excess over peptide attached, 2 min); 11, DCC in CH2CI2 (at least three-fold excess over peptide attached, 3 to 4 h); 12, CH2C12 (3x, 2 min); 13. 2-propanol (2 x. 2 min); 14. CH2C12 (6x, 2 min).
In case the ninhydrin test [12] indicated an incomplete coupling, a double-coupling was performed consisting of operations 6 through 14.
The acetylation of the X-terminus was accomplished by adding 25% acetic anhydride in methylenchloride instead of steps 10 and 11 in the coupling program. The reaction time was 20 min.
The completed peptide -BHA resin was treated with anhydrous liquid HF containing ca. 20% anisole for 1 h at 0 °C as described [13] .
Purification
The following chromatographic systems were employed: Gel filtration over Sephadex G-15 (100 X 2.75cm) in 20% AcOH (A); Sephadex G-25 (100 x2.75 cm) in 12% AcOH (B), and in 20% AcOH (C); partition chromatography over Sephadex G-25 in 1-BuOH, AcOH, water (4:1:5) (D); and chromatography over Sephadex LH-20 in 1-BuOH. AcOH, water (6:10:90) with 4-7% MeOH (E) or 1-10% MeOH (F).
Peptide peaks were located, and progress on purification was monitored on silica TL0 plates using solvent system 1. Fraction cuts were made for purity at the expense of product yield. The purity was examined in the following TLC solvent systems: (1) 1-BuOH, AcOH. AcOEt, H20 (1:1:3:1); (2) EtOH. H2O (7:3); (3) Amino acid analyses on ca. 0.5 mg samples, hydrolyzed in 6 N HCl with or without the presence of traces of phenol, were performed on a Beckman Model 119 Amino Acid Analyzer.
Optical rotations were measured in a PerkinElmer 141 digital readout polarometer. 
Biological assays
The peptides were assayed for their LHRH agonist and antagonist activities, in vitro, using rat pituitaries, and for activity to inhibit ovulation in rats, as described [10] .
Results and Discussion
The results of the in vitro and the antiovulatory assays in rats are shown in Table I and II, respectively. All of these analogs were essentially devoid of agonist activity at the highest dosages tested; for brevity, these data were omitted. The inhibitory effect on the FSH release parallels that on the LH release.
The first three analogs (1, 2. 3 in Table I) LHRH gave a structure to be described separately [14] , which is in favorable agreement with structures calculated for other potent antagonists of LHRH. These energy calculations were based upon those which had been made in 1978 for LHRH by Momany [15] .
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